ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone
EntityUAM. Departamento de Medicina; Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)
PublisherFEBS Press and John Wiley & Sons Ltd.
10.1002/1878-0261.12367Molecular Oncology 12.10 (22018): 1735–1752
ISSN1574-7891 (print); 1878-0261 (online)
Funded byThis work has been supported by Ministerio de Economía y Competitividad del Gobierno de España (MINECO, Plan Nacional I+D+i AGL2016-76736-C3), Gobierno regional de la Comunidad de Madrid (P2013/ABI-2728, ALIBIRD-CM), EU Structural Funds and AMAROUT-Marie Curie actions (COFUND2014-51539-04)
ProjectGobierno de España. AGL2016-76736-C3; Comunidad de Madrid. P2013/ABI-2728/ALIBIRD-CM; info:eu-repo/grantAgreement/EC/FP7/228526
SubjectsApabetalone; ATP-binding cassette transporter; Colorectal cancer prognosis; Reverse cholesterol transport; Medicina
Rights© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
At the time of diagnosis, 20% of patients with colorectal cancer present metastasis. Among individuals with primary lesions, 50% of them will develop distant tumours with time. Therefore, early diagnosis and prediction of aggressiveness is crucial for therapy design and disease prognosis. Tumoral cells must undergo significant changes in energy metabolism to meet increased structural and energetic demands for cell proliferation, and metabolic alterations are considered to be a hallmark of cancer. Here, we present the ATP-binding cassette transporter (ABCA1), a regulator of cholesterol transport, as a new marker for invasion and colorectal cancer survival. ABCA1 is significantly overexpressed in patients at advanced stages of colorectal cancer, and its overexpression confers proliferative advantages together with caveolin-1 dependent-increased migratory and invasive capacities. Thus, intracellular cholesterol imbalances mediated by ABCA1 overexpression may contribute to primary tumour growth and dissemination to distant locations. Furthermore, we demonstrate here that increased levels of apolipoprotein A1 (APOA1), a protein involved in cholesterol efflux and high-density lipoprotein constitution, in the extracellular compartment modulates expression of ABCA1 by regulating COX-2, and compensate for ABCA1-dependent excessive export of cholesterol. APOA1 emerges as a new therapeutic option to inhibit the promotion of colorectal cancer to metastasis by modulating intracellular cholesterol metabolism. Furthermore, we propose apabetalone, an orally available small molecule that is currently being evaluated in clinical trials for the treatment of atherosclerosis, as a new putative therapeutic option to prevent colorectal cancer progression by increasing APOA1 expression and regulating reverse transport of cholesterol
Google Scholar:Aguirre-Portolés, Cristina - Feliú Batlle, Jaime - Reglero Rada, Guillermo J. - Ramírez de Molina, Ana
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
ColoLipidGene: Signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients Vargas, Teodoro; Moreno-Rubio, Juan; Herranz Barrera, Jesús; Cejas, Paloma; Molina, Susana; González-Vallinas, Margarita; Mendiola, Marta; Burgos, Emilio; Aguayo, Cristina; Custodio, Ana B.; Machado, Isidro; Ramos, David; Gironella, Meritxell; Espinosa-Salinas, Isabel; Ramos, Ricardo; Martín-Hernández, Roberto; Risueño, Alberto; Las Rivas, Javier de; Reglero Rada, Guillermo J.; Yaya, Ricardo; Fernández-Martos, Carlos; Aparicio, Jorge; Maurel, Joan; Feliú Batlle, Jaime; Ramírez de Molina, Ana